Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States.
Saved in:
| Title: | Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States. |
|---|---|
| Authors: | Adjei K; Economic, Social, and Administrative Pharmacy (ESAP), College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Diaby V; Otsuka Pharmaceutical Companies, Gainesville, FL, USA., Li M; Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA., Sherbeny F; Economic, Social, and Administrative Pharmacy (ESAP), College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Suther S; Economic, Social, and Administrative Pharmacy (ESAP), College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Ali AA; Economic, Social, and Administrative Pharmacy (ESAP), College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA. askal.ali@famu.edu. |
| Source: | Clinical drug investigation [Clin Drug Investig] 2026 Jul; Vol. 46 (7), pp. 721-732. Date of Electronic Publication: 2026 May 29. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
